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Background: The Medical Commission is responsible for screening all newcomers and 
expatriates in Doha, Qatar to ensure that infectious diseases do not enter the country. 
The infectious disease tests include; HIV, Hepatitis B, Hepatitis C, Syphilis, and 
Tuberculosis. Aim: In this study, we aim to evaluate the diagnostic efficiency of the 
protocols used in the Medical Commission for the diagnosis of HIV and Syphilis using 
specific statistical measures. Methodology: The replicates of ELISA reading was 
analyzed and used for repeatability and reproducibility purpose. For RPR testing, a total 
of 198 syphilis reactive samples during the period of January 2019 to December 2019 
were included in this study. Results: HIV screening retrospective data has been 
collected from a total of 585,587 individuals who visited the Medical Commission, in 
which 595 were positive for HIV.  The assays obtained from these individuals for HIV 
were analyzed and compared to each other to test the reproducibility and cost-
effectiveness of this diagnosis protocol. Two rounds of HIV diagnostic results showed 
a 99.83% agreement (overall and positive percent agreements; 95% CI, 99.05-99.97%). 
For syphilis analysis, data were obtained from the RPR test performed on 198 blood 




and TPA Elisa was 36.55% (95% CI; 30.14%-43.47%), whereas the positive percent 
agreement was 100% (94.93%-100%). In order to ensure true positives, PPV results 
were obtained and were found similar to the overall percent agreement of the RPR 
dilution 2 and TBA ELISA i.e. 36.55% (30.14%-43.47%). Conclusion: The medical 
commission used highly performance techniques that are reliable and efficient for 
screening of STDs. Nevertheless, further studies are needed to test the agreement of 
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CHAPTER 1: INTRODUCTION  
Sexually transmitted diseases are defined as diseases that are transmitted 
through sexual contacts. The most common sexually transmitted infections are: 
Chlamydia, Gonorrhea, Trichomoniasis, Syphilis, and Acquired 
immunodeficiency syndrome (AIDS) caused by Human Immune Deficiency 
virus (HIV), Chlamydia trachomatis, Neisseria gonorrhea, Trichomonas 
vaginalis, and Treponema pallidum. These sexually transmitted diseases cause 
seriously urogenital symptoms such as cervicitis, urethritis, vaginitis, and 
genital ulceration, and few of these agents infect the rectum and pharynx (1). 
HIV and Syphilis are of different prevalence around the world. There are  
approximately 75 million individuals that have become infected with HIV since 
the start of the epidemic (2). On the other hand, the worldwide predominance 
of syphilis was assessed to be 1.11%. Although the percentage of syphilis is 
considerably low, the predominance of the diseases increases among districts in 
local areas in Africa (3). 
Indeed, each year, there are about 6 million new cases of syphilis 
globally due to this reason. In recent years, with the presence of HIV infection 
and its concurrence with syphilis, there has been a great focus on understanding 
the rates of syphilis and HIV coinfection (4). Such coinfection has been found 
in several cases, for example nearly 10% of Danish men analyzed with syphilis 
also acquired HIV infection (5). In addition, HIV-positive patients were found 
to be associated with sexual behaviors related to syphilis than HIV-negative 
patients (6). Because of this coinfection incidences, several methods to improve 





HIV can be diagnosed by detecting HIV antibodies (7) and/or detecting 
viral RNA, DNA, enzymes, and proteins (8) or by applying different novel 
methods (9). On the other hand, Syphilis can be diagnosed using Dark field 
microscopy, which is the most specific technique for syphilis diagnosis when 
an active chancre or condyloma latum is present (10). However, its accuracy is 
limited by the experience of the operator performing the test, the number of live 
treponemes in the lesion, and the presence of non-pathologic treponemes in oral 
or anal lesions (11). Thus, the main method for diagnosis of syphilis is non 
treponemal tests such as the VDRL test and rapid plasma reagin test. However, 
with these tests, false positive results are common because of pregnancy, 
autoimmune disorders, and infections (12). Qualitative nontreponemal tests are 
widely used for syphilis screening. However, their usefulness is limited by 
decreased sensitivity in early primary syphilis and during late syphilis, when up 
to one third of untreated patients may be nonreactive (11). Molecular methods 
such as PCR technology (13) and other novel methods (14) are also used.  
According to the Qatar Ministry of Public Health (MOPH), 
communicable diseases account for around 8% of all deaths in Qatar, negatively 
affecting the life quality of residents and creating an overwhelming concern for 
Qatar’s healthcare system (15) In addition, with the influx to the county of the 
high numbers of multi-national expatriates, Qatar continues to face a 
considerable challenge in infection control. The Medical Commission (MC) in 
Qatar works under the umbrella of the Ministry of Public Health, which 
contribute effectively to the implementation of the ministry’s general strategy. 
The MC is responsible for screening newcomers and expatriates to Qatar in 




enter the country. The Medical authorities in Qatar ensures that the country 
remains a disease-free nation, requiring individuals by law to take a medical 
exam upon arrival in the State. The medical exam is essential to protect the 
health of the entire population as a whole, but this also protects the newcomers 
themselves and making sure to avoid any spread of infectious diseases.  
In this study, we aim to evaluate the performance of the protocols for 
the diagnosis of HIV and Syphilis in the MC Laboratory. Our work will provide 
a useful benchmark information to improve the testing protocol in the medical 
commission to achieve the most reliable results with minimal cost. In addition, 
our study is the first of its kind to compare the performance of Architect 
instruments, INNOLIA and Architect, and finally between PCR and Architect 
diagnostic results for HIV and Syphilis. The aim of this study is to evaluate the 
performance of the protocols for the diagnosis of HIV and Syphilis in the 




CHAPTER 2: OBJECTIVES AND SIGNIFICANCE  
The study objective is to analyze and quantify the percentages of the 
variation between the results of the screening and confirmatory assays. 
Therefore, we hypothesize that if we could identify the amount and the source 
of the variation between assays by measuring Replicability and PPV, this will 
enable us to improve the testing protocol in the medical commission to achieve 
the most reliable results with minimal cost.  
This study is considered significant since it is expected to improve the 
replicability or reproducibility (in other words, precision) and the positive 
predictive value (PPV) which is related to sensitivity (since it will detect the 
probability of a person with positive results and having the disease)) in the 
Medical commission laboratory and should enhance Laboratory Quality 
Management System. Besides, this study considered the first of its kind to 
compare between the performance between Architect instruments, INNOLIA 
and Architect, and finally between PCR and Architect results as no study 





CHAPTER 3: LITERATURE REVIEW  
Sexually transmitted diseases (STD) have been described since the ancient 
times. The invention of penicillin is a turning point in the history of sexually transmitted 
diseases and their treatment. The post-penicillin era saw a noteworthy decrease within 
the rates of sexually transmitted diseases, particularly, syphilis. Likewise, issues of 
other sexually transmitted diseases of bacterial, fungal and viral etiology came to be 
tackled well with the invention of generations of highly potent antibiotics, antifungal, 
and antiviral drugs. Each year, an estimated 500 million people contract one of the four 
STDs i.e. Chlamydia, Gonorrhea, Syphilis and Trichomoniasis (16). In addition, the 
burden of these diseases globally increased by the emergence of AIDS. 
2.1 Types of Sexually Transmitted Diseases  
Sexually transmitted infections are a broad term which includes infections by 
bacteria, virus, protozoa, fungi, and ectoparasites that result in clinical manifestations 
involving genitalia and other parts of the body in sexual interaction (16). Of these 
infective organisms, HIV virus causing AIDS and Treponema pallidum causing 
Syphilis are considered the most important.  
2.2 HIV 
     2.2.1 Epidemiology of HIV  
2.2.1.1 Worldwide  
Around 37.9 million individuals are as of now living with HIV where the global 
predominance among grown-ups (the percentage of individuals ages 15-49 who are 
infected) has increased since 2001 to reach 0.8% in 2018. Of the individuals infected 
with HIV in 2018, 36.2 million were adults and 1.7 million were children under age 15 
(2). Figure (1) shows the worldwide prevalence of HIV in the year 2018.  HIV 
prevalence is increasing in nearly every geographic region in the world, mostly because 




drugs has dramatically improved survival among people living with HIV, yet the 






      2.2.1.2 Regional 
About 5.9 million individuals are living with HIV in Asia and the Pacific, 
whereas about 240,000 individuals are diagnosed with HIV within the Center, East, and 
North Africa (2).  
     2.2.1.3 Qatar 
             Qatar remains a low prevalence country for HIV infection. The disease affects 
mainly young male adults with many of them presenting late in the disease. The 
epidemiology of HIV infection in Qatar has changed over time with infection being mostly 
sexually transmitted in later years. Only 306 cases of HIV infections in Qatar during the 
period between 1984 and 2014, indicating that Qatar is a low predominance nation for 




HIV infection. The foremost common mode of transmission was sexual i.e. 72% and 
43% were due to blood transfusion (19). In addition, the study showed that half of the 
infected individuals were Qataris and the disease affects mainly young male adults with 
many of them presenting late in the disease. Importantly, the epidemiology of HIV 
infection in Qatar has changed over time with infection being mostly sexually transmitted in 
later years of life (19). 
2.2.2 Classification and Structure of HIV   
HIV is an enveloped virus of approximately 100 nm in diameter harboring a 
positive sense single stranded RNA genome. The virus is composed of 2 copies of the 
~10 kilobase (kb) positive sense RNA genome in the viral core, the protease, integrase, 
and reverse transcriptase enzymes (20). The trimeric transmembrane glycoprotein gp41 
is embedded in a lipid envelope, to which the surface glycoprotein gp120 is joined. In 
addition, gp41 and gp120 are two other glycoproteins that help in virus attachment. 
Beneath that layer, there are; protein p17, the center proteins p24, p6, and the 
nucleocapsid protein p7 Figure 2  (21). All those proteins are encoded by the 
viral gag gene. Other proteins include VIF (viral infectivity protein), VPR (Viral 
Protein R), TAT (Trans activator of Translation), REV (Controller of Viral Protein 
Expression) and NEF (Negative Administrative Figure). An extra protein found in HIV-
1 but not HIV-2 is VPU (Viral Protein U). Additionally, VPX (Viral Protein X) is found 














2.2.3 Pathogenesis of HIV infection 
Till now, HIV infection pathogenesis remains a fascinating topic that requires 
further studies. Infection with HIV starts without any symptoms or clinical signs, 
however, it is usually accompanied by slight decrease in the immune system (22). This 
stage spans up to 3 months after the viral infection until seroconversion where HIV-
specific antibodies can be detected in individuals following recent exposure. The 
outcome of infection and duration for disease progression with clinical symptoms may 
vary greatly between individuals, but often it progresses fairly slowly (22). It takes 
several years from primary infection to the development of symptoms of advanced HIV 
diseases and immunosuppression (22, 23). 
During primary infection, although individuals may look healthy, the virus is 
actively replicating in the patient’s lymph nodes and blood stream. Consequently, the 
immune system will get weaken slowly by the burst of viral load in their bodies (23). 
Eventually, at later stages, the patient will become susceptible to other opportunistic 
infections including; Mycobacterium avium, Mycobacterium tuberculosis, 
Pneumocystis carinii, CMV, toxoplasmosis and candidiasis. 
 




2.2.4 Diagnostic assays for HIV 
2.2.4.1 Rapid Tests 
These are based on same principle as EIA but provide faster results due to 
utilization of high antigen concentration and more sensitive color detection reagents. 
2.2.4.2 Confirmatory Assays 
IFA (Immunofluorescence Assay) has been largely replaced by Western Blotting 
(WB) and LIA (Line Immunoassays). But unlike EIA, none of these can detect IgM 
Antibodies or viral antigens and are more expensive. Hence, serial or parallel EIA 
testing algorithms can suffice at a much-reduced cost in resource-poor settings. The 
rapid test that comes about is affirmed by Western Blot measure. Although fast tests 
are fast and simple as they can use capillary blood, plasma, and serum as a sample or 
even urine or oral secretion, they are less sensitive than other tests. The base of rapid 
tests is immune-chromatographic methods as well as particle agglutination and immune 
filtration techniques (24). Besides, usually the HIV positive samples are confirmed by 
INNOLIA confirmatory test.  
 The advanced quality HIV Rapid Test is used to diagnose HIV in South Africa 
to screen for a positive HIV diagnosis. In Bhowan et al study, they tested the 
performance of the fourth generation of the rapid test and found that it had no better 
results than the third generation of the same rapid test (7). If a pink line appears in either 
the HIV antibody window or the HIV p24Ag window or both of the windows, then HIV 
is positively diagnosed. The test is considered substantial as if the positive control is 





2.2.4.3 Architect  
One of the automated assays that are based on the EIA idea and is widely used 
in many countries in the world including Qatar is Architect (Figure 3) (25). 
ARCHITECT® HIV Ag/Ab Combo is an in vitro chemiluminescent microparticle 
immunoassay that detects HIV p24 antigen and antibodies to HIV-1 and/or HIV-2 in 
human serum and plasma. It is fully automated and takes ~30-minutes time to detect 
the first result. Its overall specificity is 99.77% (95% CI: 99.62-99.88%), HIV antibody 
sensitivity is 100% (95% CI: 99.63- 100.00%), and HIV p24 Ag explanatory 
affectability is 18.39 pg/mL (run 17.80-19.68 pg/mL). HIV Combo recognizes HIV 
diseases during the early, late, and intense stages of the infection (26). The evaluated 
performance of the ARCHITECT HIV Ag/Ab kit (Abbott) in African setting-Cameroon 





There are several Architect immunoassays I Abbott types: 
1-The ARCHITECT i2000SR immunoassay analyser 
• It has a maximum throughput of up to 200 tests per hour 
• It features a load-up capacity of 135 samples with 35 priority and 100 
routine areas 
• It consists of 25 refrigerated reagent positions 
2-The ARCHITECT i4000SR immunoassay analyzer 
• It offers a maximum throughput of up to 400 tests per hour 
• It Features a load-up capacity of 285 samples with 35 priority and 250 
routine areas 
• It consists of 50 refrigerated reagent positions 
 








2.2.4.3 Molecular methods  
Molecular Assays are important in HIV diagnosis, and detection of acute 
infection (9). PCR and NAAT are used for detecting viral RNA, DNA, enzymes, and 
proteins. These methods are useful for early diagnosis in infants born to seropositive 
mothers, diagnosing acutely infected individuals in specific periods and assessing viral 
load for follow-up of infected patients. Using qualitative PCR, viral nucleic corrosive 
is amplified to distinguish HIV while quantitative RNA, PCR is used to screen HIV-
Positive Patients and to choose when HIV treatment ought to begin (24).  
Bhowan et al.(2012), stated several advantages for these rapid tests for HIV 
detection, including ease of administration, ease for patients, rapid results to reduce loss 
to follow-up and help initiate treatment immediately as well as needing no special 
instrumentation (7).  
They also stated that it costs less than serological tests. These findings have 
confirmed the superiority of NAAT tests was found over rapid serological tests. The 
sensitivity for early HIV detection was only 22% -33% compared to a sensitivity of 
76%-88% for the fourth generation of NAAT tests. They suggested that programs that 
use rapid tests for HIV detection switch to NAAT or other antigen-based tests (27).  
Also, a one-step TaqMan NAT qRT-PCR strategy for the location of HIV RNA 
was created where they observed linearity over a range of 1 × 102 to 1 × 107 IU/ml and 
a lower limit of detection of 100 IU/ml (28). The Cobas Taqscreen MPX test may be a 
nucleic corrosive enhancement method. This test first isolates the purified nucleic acids 
from human plasma, and then the second step is the amplification and discovery of 
HIV-1, HIV-2, HCV RNA, and HBV DNA. Finally, it is actuated by the expansion of 
manganese acetic acid derivation, turn around translation (for RNA targets) continues, 




HCV RNA, and HBV DNA using specific primers (28). Although the sensitivity of 
molecular RNA assays is remarkable in acute HIV, their specificity can be a problem 
due to false negatives in 5% of the cases. In addition, NAATs can be expensive and 
time consuming (29). 
2.3 Syphilis  
Syphilis is an STI that is caused by the Treponema Pallidum, which is a spirochete 
bacterium (30, 31). 
     2.3.1 Epidemiology of Syphilis 
     2.3.1.1 Worldwide  
There were 10.6 million new cases of syphilis in 2008. It has been previously 
known to happen essentially in people between the age groups of 15 and 40, however, 
it has been also reported that around 1 million newborn children are born each year with 
innate syphilis (Figure 4) (32). 
 
  





     2.3.1.1 Regional  
Major differences were recorded between different regions in the world, however 
the highly affected region that showed consistent infection was Africa (3). Figure 5 
summarize the findings of their study.  
 
 






     2.3.1.1 Qatar  
Although no exact statistics are available about the prevalence of syphilis in 
Qatar, a reported that countries with population making high salaries have a low 
tendency for the infection as compared to those countries with the majority of its people 
being either poor or of low income. Therefore, as a high-income country, it can be 
concluded that Qatar has in general a low prevalence of Syphilis (1).  
     2.3.2 Classification and Structure of Treponema pallidum 
 
T. Pallidum Subspecies Pallidum is a spirochete with the smallest circular 
chromosome among prokaryotes that is only of ~1.1 kb in length. As a typical member 
of the spirochete family, T. pallidum is a gram-negative spiral shape bacterium with 
both outer and cell membranes with a periplasmic space harboring the flagella (endo 
flagella). The bacteria possess three to six flagella that give it the ability of great motility 
Content adjusted odds 
ratio (AOR) 
Percentage  CI 
Americas 0.42 95% 0.33-054 
Eastern 
Mediterranean 
0.13 95% 0.09-0.19 
Europe 0.05 95% 0.03-0.07 
South-East 
Asia 
0.21 95% 0.16-0.28 
Western Pacific 0.41 95% 0.32-0.53 
 




and ability to pass through different membranes. Importantly, the bacteria possess inner 
membrane lipoproteins that had showed strong reactivity with syphilis patients’ serum 
at different stages of the disease (5). 
2.3.3 Pathogenicity of Treponema pallidum                     
2.3.3.1 Pathogenesis 
The clinical course of syphilis is extremely varied and is interrupted by various 
phases of variable duration as shown in Figure 6. Primary chancre presents as a well-
defined ulcer with regular raised or rolled out edges and a clean base. The chancre may 
be tender due to secondary bacterial infection and may occur in extragenital sites like 
oral, anorectal, breast and digits. Secondary Syphilis presents with a rash that is non-
vesicular, non-pruritic and bilaterally symmetrical (16). 
2.3.3.2 Virulence factors 
Several virulence components had been identified for T. pallidum's capacity to 
cause infection. One of which is hemolysin that counts as a crucial factor that lysis 
cell membranes and helps the bacteria entry (32). 
2.3.3.3 Risk factors  
Risk factors include different sex practices, which is either not using protective 
measures or are abnormal practices such as anal sex and sedate utilization (6).  
2.3.3.4 Modes of Transmission 
The fundamental course of syphilis transmission is sexual contact; however, 
syphilis can additionally be transmitted through blood, intrinsically, and through non-
sexual contact with syphilitic injuries on skin or mucosa. Also, transplacental infection 
















2.3.3.5 Host genetic determinants  
Genome-wide affiliation ponders have distinguished a few hereditary 
factors/susceptibility loci that are associated with irresistible diseases. Host genetics 
can determine susceptibility and resistance to infectious disease. Affirmation of the 
components that decide why few individuals who are uncovered to T. pallidum do not 
create an infection, is required to get its defensive insusceptibility against T. pallidum 
(33). 
2.3.4 Diagnosis of Syphilis 
2.3.4.1 Serological methods 
The main method used to diagnose syphilis remains serological testing in spite 
of the fact that these tests cannot distinguish between syphilis and other 
treponematoses (5). Serological tests for syphilis consist of two types, non-treponemal 
and treponemal tests. Non-treponemal tests have high sensitivity but low specificity. 
Taking into consideration that, viral infections, including HIV and HCV infections 
can lead to false-positive test results, patients with receptive non-treponemal tests 
could have corroborative treponemal tests done to confirm the diagnosis (5). Non-
treponemal assays include the rapid plasma regain (RPR) and venereal infection 
investigate research facilities (VDRL) tests, which measure antibodies to lipoidal 
products. In spite of the fact that non‐treponemal tests are viable, cross‐reaction 
happens regularly in case of pregnancy and immune system illnesses such as 
rheumatoid joint pain which could be seen particularly in early syphilis stages.   
Treponemal tests are expensive, time‐consuming, and actually troublesome to 
perform since this bacterium is entirely endobiotic (34). Treponemal tests detect 
antibodies specifically secreted against T. pallidum proteins. On the other hand, new 




and polyvalent conjugates that distinguish both IgM- and IgG-class antibodies to 
syphilis. In fact, it has been shown that treponemal assays are more sensitive in primary 
syphilis and false positive results are not common (35). It is considered that the non-
treponemal tests, treponemal tests and single pathogen rapid detection tests are all basic 
set of screening tools for syphilis (36). 
In a study by Salado (2015), three treponemal tests were used. The first was 
anti-flagellum determined by a capture ELISA, the second was anti-flagellum decided 
by a circuitous ELISA, and the third was the Fluorescent Treponemal antibody 
absorption test done by immunofluorescence microscopy. Combined with specific 
antibody testing, a Rapid Plasma Regains (RPR) test permits to confirm the conclusion 
of dynamic disease and to begin treatment. This diminishes the chances of 
complications and the spread of the disease (5).  
The RPR test is used to diagnose syphilis, where it measures antibodies that are 
present in the blood of syphilis patients, rather than the bacterium that causes the 
disease. In addition, the RPR test can moreover be utilized to check the advance of 
treatment for dynamic syphilis. After a course of successful anti-microbial therapy, it 
is expected to see the titer of antibodies drop, and an RPR test confirms these results. 
However, syphilis cannot be really ruled out if there are no antibodies, because it takes 
time for the antibodies to be formed after infection. Thus, shortly after an infection, a 
test may not yet show positive test for the antibodies, which is often known as an un-
true negative. On the other hand, there are many conditions that can cause an un-true 
positive incorporate HIV, Lyme Illness, Jungle Fever, and Lupus.  
Due to the chance of false-positive results appearing, a confirmatory test is usually 
being done by diluting the samples or by using other assays. For example, there are two 




for screening and detection of active disease and for monitoring of the response to 
treatment. The other test is the treponemal test like TPA which is used as a confirmatory 
test (37). The use of direct diagnostic methods is limited and that serological tests and 
treatment calculations contrast from nation to nation (5).   
2.3.4.2 Molecular methods  
The Polymerase Chain Reaction (PCR) method to detect T. pallidum and hence 
to diagnose syphilis has been used since 1990 (5). PCR is the most common molecular 
method used to detect treponemal DNA or antigen in early essential syphilis, early 
intrinsic syphilis, and neurosyphilis where the application of treponemal serologic tests 
are constrained. Its affectability in different tissue liquids inspected was 78% 
comparing with the rabbit infectivity test. Different types of PCR based methods 
include schedule PCR, Settled PCR, Real‐Time PCR, And Multiplex PCR, these are 
the ones with the quickest improvement, most extensive application, and most profound 
investigation over the past decade.  Schedule PCR and Multiplex PCR can be utilized 
within the early arrange when the serological response is negative, whereas, settled 
PCR and real‐time PCR can be used for confirmation. They found that multiplex PCR 
had the highest sensitivity and specificity among the PCR methods mentioned above, 
almost 100% in all cases. However, as Salado (2015) pointed out, the samples matrix 
and disease stage can affect the success rate of the diagnostic PCR Moreover, the 
multiplex PCR test separates syphilis, herpes simplex and chancroid in genital ulcer 
(38). 
 Zhou et al. (2019) mentioned the other four types of molecular methods, which 
are dark‐field Microscopy (DFM), Silver Recoloring, Coordinate Fluorescence 
Immunoassay (DFA), and the Rabbit Infectivity Test. The authors pointed out that the 




from the lesion seen beneath the magnifying lens with a dark-field condenser with 
indirect light (34). It is not expensive and its sensitivity ranges from 74 to 86% and can 
be higher. Another method is the Fontana-Thibodeau method, where the lymph is 
smeared on a slide with the addition of silver, which impregnates the treponema wall 
and makes it visible (39).  
In molecular diagnosis, the specimen is collected and then NA is extracted 
followed by the amplification or hybridization and finally analyzed. Nucleic acid 
hybridization techniques, amplification techniques, and strain typing, and identification 
are all types of molecular methods. The target amplification incorporates PCR, real-
time PCR and inverts transcription-PCR. Multiplex PCR where both CT and NG are 
included in a single PCR tube is also used to diagnose syphilis (40). 
2.4 Syphilis and HIV co-infection 
An interesting study found that HIV co-infection had an effect as it was on the 
serological reaction in patients with syphilis and a CD4 cell count of <500 cells/μl (41). 
In this study it has been observed that HIV infected patients are at significantly high 
risk to get infected with syphilis (IRR = 4.0, 95% CI 2.8–5.9). In fact, HIV coinfection 
has been illustrated to be vigorously related to syphilis (6). Moreover, Salado (2015) 
noticed the higher frequency of treatment failures of syphilis among HIV infected 
patients and concluded that it was most likely due to low immunity in patients infected 
with HIV (5). 
2.5 Medical Commission (MC) 
 
MC in Qatar works under the umbrella of the Ministry of Public Health, and it 
contributes, on a large scale, to the implementation of the ministry’s general strategy in 
an effective manner. In 2019, MC department screened around 607,601 with an average 





The MC Vision is to screen all newcomers and residents for the following 
purposes: 
1 Health screening to obtain Medical fitness certificate to apply for a job, travel, or 
university study in-state 
2 Annual Health screening to obtain health certificate for those working either as 
food handlers, barbers and beauticians, or for individuals in any health club 
3 Health screening can also be done for acquiring QCHP license 




CHAPTER 4: METHODOLOGY 
3.1 Ethical consideration 
IRB exemption was obtained from Qatar university (QU) and Ministry of Public 
Health (MOPH) IRB. 
3.2 Inclusion and Exclusion Criteria and number of samples 
All initial reactive/positive for HIV1-2 Ag/Ab Combo and RPR blood samples 
that were collected from 1st January 2019 to 31st December 2019, were included and 
analyzed. We included 595 HIV positive samples and 198 Syphilis positive samples in 
our study. 
3.3 Recruitment Methods 
This is a retrospective study. Thus, no patients/applicants were recruited and 
there was no direct or indirect interaction with a human subject. The study was 
conducted on existing de-identified testing results in the MC database. 
3.4 Confidentiality 
The study was conducted on de-identified data and the data was saved in the MC’s 
password-protected database medic system and the students limited access from the 
section head for de-identified test results information. All samples were bar-coded. In 
addition, all sample results were stored in the medic system database and password-
protected to preserve applicants’ identities. 
3.5 Data collection and statistical analysis 
According to our sample size calculation (based on Stephen Thompson equation, 
explained in the section below), a total of 595 samples tested positive for HIV1-`2 
Ag/Ab Combo collected during the period of January 2019 to December 2019 using 
Architect from Abbott (USA) and were included in the study. The Replicate ELISA 
reading is analyzed and used for repeatability and reproducibility purposes. We also 




confirmatory test and HIV 1 PCR and analyzed for Positive Predictive Value (PPV), 
true positive, and false positive results.  
Moving on to the RPR testing, a total of 198 syphilis reactive samples during the 
period of January 2019 to December 2019 were included in this study. The results of 
T. Palladium Antibody (TPA) confirmatory test for these 283 RPR reactive samples 
were also included and analyzed for PPV, true positive, and false positive results.  
All demographical data related the patient's nationality was classified as a 
continent, patients’ gender, and age were also obtained from the MOPH for statistical 
analysis. The data are saved in the MOPH and kept confidential. No names or any 
patients’ identification was collected. The test measure was calculated based on the 
confidence level using the Stephen Thompson equation, which was one of the best 
equations for calculating the sample size. The sample size was calculated based on the 
confidence level using the Stephen Thompson equation, which is one of the best 
equations for calculating the sample size. As the confidence level of the sample 
increases, the sample size increases, and the margin of error will decrease. 
                               
 
 
N: Population size. 
Z: standard value of the significant level ( 95% ) and it equals (1.96). 
D: error ratio and it equals (0.05) 
P: The ratio of the availability of the property and the neutral and equals 0.50. 
  
( )












3.6 Routine work in MC 
 
3.6.1 HIV Ag/Ab Combo Test for HIV Detection 
For the detection of HIV p24 antigen and antibodies, we have used the 
ARCHITECT HIV Ag/Ab combo assay. This was a qualitative assay that had the 
advantage to simultaneously detect both p24 antigen and antibody of HIV-1/HIV-2. 
However, the results of this assay cannot distinguish between the detection of HIV p24 
antigen, HIV-1 antibody, or HIV-2 antibody reactivity. This assay was performed 
according to the manufacturer protocol. Briefly, human serum containing p24 antigens 
and antibodies were combined with a mixture of assay diluent, washing buffer, and 
paramagnetic microparticles coated with HIV-1/HIV-2 antigen and HIV p24 mouse 
monoclonal antibody.  
After an incubation period of the samples was washed with the washing buffer 
to get rid of any unbound complexes. After the final wash cycle, pre-trigger and trigger 
solution were added to the reaction mixture and the resulting chemiluminescent reaction 
is measured as relative light units (PLUs). This signal indicated the presence or absence 
of the antigen or antibodies (exist indirect relationship) in the sample and it was 
compared to the cut-off signal determined from the assay calibration. The signal to cut-
off (S/CO) values determines if the sample was positive or negative to HIV. Samples 
showing S/CO values ≥ 1.00 were considered reactive (R) to HIV-1 p24 antigen or 
HIV-1/HIV-2 antibodies, whereas those ≤ 1.00 are non-reactive. Any samples that 





      3.6.1.1 Interpretation of the Results 
1. Specimens with s/co values< 1.00 are considered nonreactive (NR). 
2. Specimens with s/co values> 1.00 are considered reactive (R). 
ARCHITECT HIV Ag/Ab combo Results: -  
· If the first test was reactive it should be rerun in duplicate.  
· If both were non-reactive, the result was considered non-reactive.  
· If one or both tests were reactive, the result should be considered reactive.  
 3.6.1.2 Specificity  
The Specificity is > or equal 99.5 % with 95% confidence interval. 
3.6.1.3 Sensitivity  
The sensitivity is as per package insert of the manufacture the Anti-HIV-
1sensetivity is 100%, HIV-2 also 100% and HIV group O is 100%. An average 
responsiveness to HIV-1 p24 Ag of 18.06 Pg./ ml. 
3.6.2 - INNOLIA Test (Confirmatory test) 
To affirm the nearness of antibodies against (HIV-1) in positive samples, we have 
used the INNO-LIA™ HIV I/II Score. This assay was a Line Immune Assay (LIA®) that 
could distinguish between HIV-1/HIV-2, where on a nylon strip discrete lines of HIV-1 and 
HIV-2 recombinant proteins and engineered peptides are coated (Figure 6). This could 
detect HIV-1 antibodies to the structural proteins gp120, gp41, p31, p24, and p17, 
conjointly cross-react with HIV-2 antibodies. In addition, it also could detect Antibodies 
specific to HIV-2 gp36 and sgp105. This test was performed agreeing to the producer 
protocol. Briefly, the sample was incubated with the strips mentioned above. A goat 
antihuman IgG named with Antacid Phosphatase was then included to the antigen-antibody 
complex. Finally, the enzyme was incubated with the substrate (BCIP/NBT) and the results 




show up. The thickness of the color reflected the number of antibodies present in the 
sample. Moreover, color development was stopped with sulfuric acid. In case the sample 
was negative, a background color would appear. All results were compared to the anti-
streptavidin and human IgG positive controls. The human IgG positive controls give 
different color intestines indicating, a range from weak (+) to strong (+++) control lines. 
3.6.2.1 Interpretation of the results 
1. If there was no line positive and negative, the sample was considered as negative. 
2. If there are two or more lines positive and negative, the sample was considered as 
indeterminate. 
3. If a ratio of positive and negative was got on both ENV2 antigen line, the sample 
was considered as a positive. 
4. If a ratio of positive and negative was got on both ENV1 antigen lines, the sample 
was considered as positive 
3.6.2.2 Sensitivity 
As a package insert, the sensitivity was 100% for HIV1 and HIV2. 
3.6.2.3 Specificity  





Figure 7 INNOLIA test machine. 
 
3.6.3 Diagnosis of HIV in MC 
 
As shown in Figure 8, if the first sample results are negative, then the results 
will be released without confirmation test. If the first sample result is positive, the same 
sample will be rerun twice in the same machine. If the first sample results are positive 
and rerun sample is positive, its consideration as positive. If the first sample result is 
positive and one of rerun is positive and the other is negative, delete negative and 
release and consider sample as positive. Transfer the results to doctor for a decision. 
Call the applicant for new samples (one sample for repeat test and other for PCR). New 
sample running in other machine and another technician with the same technique. If the 
result of new sample is positive or negative, we rerun the sample twice. If new sample 
is positive, rerun sample, however, if negative centrifuge the sample for 10 minutes and 
rerun twice. If new sample is positive and one rerun sample one positive and the other 
one is negative, delete the negative and release the positive result. If the new sample 





3.6.4 COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, version 2.0 
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, version 2.0 (v2.0) 
is an in-vitro nucleic acid amplification test that is used for the quantitation of Human 
Immunodeficiency Virus Type 1 (HIV-1) RNA in human plasma using the COBAS® 
AmpliPrep Instrument for automated specimen processing and the COBAS® 
TaqMan® Analyzer or COBAS® TaqMan® 48 Analyzer for automated amplification 
and detection. 
 The test can help in quantitating HIV-1 RNA over the range of 20 - 10,000,000 
copies/mL (33 to 1.67 x 107 International Units [IU]/mL). In addition, one copy of 
HIV-1 RNA is equivalent to 1.67 IU based on the WHO 1st International Standard for 
HIV-1 RNA for Nucleic Acid-Based Techniques (NAT) (NIBSC 97/656) 36.  
The test is generally intended for use in combination with clinical manifestation 
and other laboratory markers of disease progress that are used for the clinical 
management of HIV-1 group M and HIV-1 group O infected patients. Moreover, the 
test can be used to evaluate patient prognosis by determining the baseline HIV-1 RNA 
level or to screen the effects of antiretroviral therapy by measuring deviations in EDTA 
plasma HIV-1 RNA levels during the period of antiretroviral treatment.  Furthermore, 
COBAS AmpliPrep/COBAS TaqMan HIV-1 Test v2.0 is not proposed to be used as a 
screening test for the presence of HIV-1 in blood or blood products or as a diagnostic 





3.6.4.1 Principles of the Procedure 
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 is actually a 
nucleic acid amplification test used for the quantitation of Human Immunodeficiency 
Virus Type 1 (HIV-1) RNA in human plasma. The COBAS® AmpliPrep/COBAS® 
TaqMan® HIV-1 Test, v2.0 is based on three major processes: (1) specimen 
preparation to separate HIV-1 RNA; (2) reverse transcription of the target RNA to 
produce complementary DNA (cDNA), and (3) simultaneous PCR amplification of 
target cDNA and the identification of cleaved dual-labeled oligonucleotide detection 
probe that is specific to the target.  
The COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 authorizes 
automated specimen preparation which is followed by automated reverse transcription, 
PCR amplification and detection of HIV-1 target RNA and HIV-1 Quantitation 
Standard (QS) Armored RNA. The Master Mix reagent contains primers and probes 
that act specific for both HIV-1 RNA and HIV-1 QS RNA. The Master Mix has been 
established to guarantee equivalent quantitation of group M subtypes of HIV-1 and of 
HIV-1 group O.  
In addition, the detection of amplified DNA is done using target-specific and 
QS-specific dual-labeled oligonucleotide probes that allows for independent 
identification of HIV-1 amplicon and HIV-1 QS amplicon. The quantitation of HIV-1 
viral RNA is accomplished using the HIV-1 QS. It is used to compensate for effects of 
inhibition and controls the preparation and amplification processes, allowing a more 
accurate quantitation of HIV-1 RNA in each specimen. The HIV-1 QS is a non-
infectious Armored RNA construct that contains HIV sequences with same primer 
binding sites as the HIV-1 target RNA and a unique probe binding region.  




amplicon. The HIV-1 QS is added to each specimen at a known copy number and is 
run through subsequent steps of specimen preparation, reverse transcription, 
simultaneous PCR amplification and detection of cleaved dual-labeled oligonucleotide 
detection probes. The COBAS® TaqMan® Analyzer or COBAS® TaqMan® 48 
Analyzer is used to calculate the HIV-1 RNA concentration in the test specimens by 
matching the HIV-1 signal to the HIV-1 QS signal for each specimen and control. 
3.6.4.2 Specificity 
The specificity of the test was calculated based on a total sample size of 566 
HIV-negative sample. A total of 562 (99.3%) samples tested true negative while 4 
(0.7%) samples were false positive. 
  The specificity of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, 
v2.0 was determined with two reagent lots by analysis of HIV-1-negative EDTA plasma 
specimens from blood donors. A total of 660 individual EDTA plasma specimens 
indicated valid results where all the results were negative for HIV-1 RNA in the 
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0. Based on these results, 
the specificity of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0 
came out to be 100% (one-sided lower 95% confidence limit: ≥ 99.6) 
The clinical sensitivity of the COBAS® AmpliPrep/COBAS® TaqMan® HIV-
1 Test, v2.0 was defined as the percentage of evaluable HIV-1-positive subjects who 
obtained a positive COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 Test, v2.0.  
3.6.4.3 Sensitivity 
The sensitivity of the test was calculated based on a total sample size of 418 
HIV-1-positive sample. A total of 418 (100%) samples tested true positive while no 



















3.6.5 Rapid Plasma Reagin RPR Test (Omega diagnostics of syphilis) 
For the detection of syphilis, we used the Rapid Plasma Reagin (RPR) card test. 
This was qualitative and semi-quantitative non-treponemal flocculation assay used to 
detect regain antibodies in serum of patient samples.  The principle of this assay was 
based on the presence of carbon particles in the antigen, which when bind to antibodies 
improved the visual reading of the flocculation reaction. This reaction could be 
observed macroscopically as black clumps when the interaction occurs cholesterol/ 
cardiolipin/ lecithin in the reagent and the reagin antibodies in the sample. The 
formation of these clumps is considered a positive reaction to syphilis, whereas a 
nonreactive negative result is indicated by no visual flocculation.  
This assay was performed according to the manufacturer protocol. Briefly, 50 
μl of patient sample was placed and spread accurately to cover a defined circle in the 
RPR Test Card. Then 16 μl of the antigen (provided by the manufacturer) was added to 
the sample and mixed by rotation 100 rpm for 8 minutes on an automatic rotator.  
Antigen-antibody interaction to detect black clumps was then observed visually 
under the light. Positive samples were then subjected to semiquantitative analysis, 
which was done as follows: A two-fold serial dilution of the patient serum sample was 
done using isotonic saline. Then 16μl of the antigen was be added to each dilution and 
the assay was completed as mentioned above. Positive and negative controls supplied 





3.6.5.1 Results and interpretation 
As shown in Figure 8 and 9, Manual test (Use carbon coated antigen). If the 
sample result is negative, consider as negative. However, if the sample result is positive, 
make a dilution to find the titer. Make a dilution by using isotonic saline 0.9% NaCl. 
Release the results and send it to the doctor. Doctor make the decision to send the 
positive sample to HMC for confirmatory test. 
Qualitative Method:  
• Positive (reactive): Medium and large aggregates or clumps.  
• Weak positive (reactive): Finely dispersed aggregates.   
• Negative (non-reactive): No aggregates visible with smooth grey appearance. 
Semi-Quantitative Method:  
The titer of the antibody was calculated based on the last dilution showing a 








































3.7 Routine Work in HMC: 
 
3.7.1 TPHA Bio rad 
 TPHA kits are intended for usage of the qualitative and semiquantitative 
detection of antibodies to Treponema pallidum that could be present in human serum 
and plasma. The product may be utilized for the screening of blood donors, and also to 
assist in the diagnosis of patients where syphilis infection is suspected. 
Principles of the Procedure  
TPHA kits use preserved avian erythrocytes coated with antigens of T. pallidum 
(Nichols strain), which will bind with specific antibody present in patient’s serum or 
plasma. The cells are suspended in a medium containing component that helps in 
eliminating non - specific reactions. Positive reactions are usually demonstrated by 
agglutination of the cells, negative reactions are demonstrated by the settling of the cells 
to a button or small ring. 
Even though these kits are meant for use primarily as qualitative tests, antibody 
levels can be titrated by doubling dilution as well.  
Agglutination patterns can be interpreted through naked eye or through a plate-
reader which can read agglutination patterns Figure 10. A contact to the concerned 
company can be made in case of adaptations and special procedures. 
 In general, there are five potential results of any tested sample. The sample is 
considered strong positive when full cell pattern covers the bottom of the well with 
negative result in the control. A weak positive result is when the pattern covers 1/3 of 
the well bottom and control cells tested negative. Equivocal samples have cell patterns 
that shows distinctly open centers. Non-specific reaction will have both test and control 











A total of 5032 samples from blood donors, prospectively gathered at 2 different 
sites, were studied. The samples were either serum (3626), EDTA K2 (539) or Lithium 
Heparin plasma (867) that were tested in a period of less than 7 days after sampling. 
They were then compared to the screening assay used in the laboratory. 
The total specificity on the blood bank population equates to 99.72% (5017/5031) with 
a 95% confidence interval of 99.53% to 99.85%. In terms of the 14 false positive 
samples, 11 were discovered to be repeated equivocal. 
A retrospective study was also carried out on 201 frozen samples from patients 
who belonged to a Sexually Transmitted Disease Center or vendors. The samples were 
found negative for syphilis. Specificity on these samples was found to be as 99.5% 







The sensitivity study was studied on 435 retrospective frozen serum samples 
from the laboratory of Sexually Transmitted Disease Center, or from frozen samples 
from vendors. These samples were described as positive by immunoassays, FTA assay, 
RPR/ VDRL assay or TPHA assays according to their sources or origins. All the 
samples were first tested with the utilization of CE mark TPHA assay and later with the 
Bio-Rad TPHA 500 assay (72504). Sensitivity on this population was found to be at 





CHAPTER 5: RESULTS 
5.1 Comparison between different methods used in HIV diagnosis: 
  Retrospective data had been collected from a total of 585,587 individuals who 
visited the MC in the period between January 1, 2019 and December 31, 2019. Among 
the total of 585,587 individuals, we found 595 positive samples. This data was obtained 
from two different rounds of ARCHITECT assay as well as from INNO-LIA HIV and 
PCR that were used as confirmatory tests. The ARCHITECT and INNO-LIA HIV 
assays were done at the MC laboratory, whereas PCR was done at HMC. It is worth 
noting that the ARCHITECT assay was performed in two different ARCHITECT 
machines (analyzers A and B) and done by two different technicians, hence, named 
rounds 1 and 2, respectively. The results obtained from all these assays were analyzed 
and compared to each other to test the reproducibility and cost effectiveness of this 
diagnostic protocol.  
In the initial HIV screening (round 1), the ARCHITECT assay identified all the 
595 tested samples positive to HIV. To confirm such reactivity, blood samples were 
recollected from all positive cases and round 2 of ARCHITECT assay was done using 
analyzer B. From this analysis, one sample was negative to HIV and 594 were HIV 
positive as shown in Table 2. 
The results were then compared to those obtained from the first round of 
screening (ARCHITECT analyzer A; round 1) using percent agreement analysis. The 
two rounds showed a 99.83% agreement (overall and positive percent agreements; 95% 
CI, 99.05-99.97%) (Table 6). Next, it was important to compare the results obtained 
from round 2 analysis with those obtained from INNO-LIA HIV and PCR. The INNO-
LIA HIV assay correctly identified 173 HIV positives, 371 HIV negatives, and 50 
Indeterminate (Table 3). Indeterminate samples mean that there was a possibility of the 




The overall percent agreement (95% CI) between the results obtained from 
INNO-LIA HIV and round 2 ARCHITECT analyzer B was then calculated. Even 
though, low overall percent agreement of 31.8% (28.3%-35.83%) was observed 
between the two assays. the positive percent agreement (95% CI; 97.83%-100%) was 
100% as shown in Table 6. To ensure these results indicate the true positive cases, we 
calculated the positive predictive value (PPV). Similar to the results obtained for the 
overall percent agreement of the ARCHITECT analyzer B and INNO-LIA, the PPV 
was 31.8% (95% CI; 28.3%-35.83%) (Table 6).   
Comparable results were obtained with the PCR analysis that showed 157 HIV 
positive samples and 429 negative ones (Table 4), with an overall percent agreement of 
26.79% (95% CI; 23.36%-30.52%) and positive percent agreement of 100% (95% CI; 
97.61%-100%) (Table 6). As expected, the PPV value was similar to the overall percent 
agreement indicating the true positive HIV cases to be 26.79% (95% CI: 23.36% - 
30.52%). 
Finally, we compared the results obtained from the two confirmatory tests (PCR 
and INNOLIA). Both assays showed the same results in a total of 525 samples, where 
155 were HIV reactive, 370 non-reactive, and one was indeterminate. However, there 
was discrepancy in 49 samples that showed reactivity in INNOLIA but not in PCR 
(Table 5). Interestingly, the agreement between the two assays was high as it reached 
97.77% (95% CI; 96.14%-98.72%) and 93.94% (95% CI; 89.21%-96.68%) in overall 









Table 1 Comparison between ARCHITECT anti-HIV round 1 and round 2 
 
 




Table 3 Comparison between ARCHITECT anti-HIV round 2 and PCR 
 
  
ARCHITECT HIV Ag/AB Combo Round2 
Positive Negative 
ARCHITECT HIV Ag/AB Combo Round1 
Positive 594 1 
Negative 0 0 
INNO-LIA HIV 
Positive Negative Indetermined 
ARCHITECT HIV Ag/AB Combo Round2 
Positive 173 371 50 
Negative 0 0 0 
PCR 
Positive Negative 
ARCHITECT HIV Ag/AB Combo Round2 
Positive 157 429 




Table 4 Comparison between INNO-LIA HCV and PCR 
 
 

































































     


















Order of reference standard:  INNO-LIA HIV 1,2 > PCR-H1V1 > ARCHITECT HIV 1,2 
Ag/Ab Combo Round 2 > ARCHITECT 
 
INNO-LIA HIV 
Positive Negative Indetermined 
PCR 
Positive 155 1 1 




5.2 Comparison between different methods used in syphilis diagnosis: 
For syphilis analysis, data was obtained from the RPR test performed on 97,298 
blood samples (collected between January 1, 2019 and December 31, 2019) to screen 
for the disease. Among the total of 97,298 individuals, we found 198 positive samples. 
The test was done in two different dilutions (1 and 2) and by two different technicians 
and the Medical Health Commission laboratory. The results from the two dilutions were 
compared and, in both dilutions, all the 198 samples tested were reactive to syphilis 
(Table 7). Indeed, this full agreement between both dilutions was confirmed with the 
agreement analysis that showed an overall and positive percent agreement of 100% 
(95% CI; 99.72-100%) (Table 9).  
The results obtained from the RPR was further confirmed by TBA ELISA 
(Done in Hamad Medical Corporation). We also collected the data produced from this 
confirmatory test and compared it to those of RPR dilution 2. In contrast to the results 
obtained from RPR dilution, TBA ELISA identified 72 syphilis positive samples and 
125 negative samples (Table 8). In line with this, the overall percent agreement between 
the two assays was 36.55% (95% CI; 30.14%-43.47%), whereas the positive percent 
agreement was 100% (94.93%-100%) (Table 9). To ensure true positive cases, the PPV 
was calculated. Similar to the results obtained for the overall percent agreement of the 






Table 6 Comparison between RPR dilution 1 and 2 
 
 
Table 7 Comparison between RPR dilution 2 and ELISA 
 
 










































RPR Dilution 2 
Positive Negative 
RPR Dilution 1 
Positive 198 0 
Negative 0 0 
TPA ELISA 
Positive Negative 
RPR Dilution 2 
Positive 72 125 




CHAPTER 6: DISCUSSION 
In the present study, we were able to show that Abbott ARCHITECT HIV 
Ag/Ab Combo assay could be used efficiently in the MC for HIV screening. The assay 
performs with high sensitivity and specificity with the two rounds repeats done on two 
different analyzers and by two different technicians. This high sensitivity and 
specificity indicate that the protocol used in MC is highly accurate in performing the 
assay as an initial screening for HIV. This is an extremely important finding because it 
significantly decreases the chances of false positives or false negatives, which in-turn 
decrease the number of people who can potentially receive wrong information about 
their health status. False reactive test results can also occur due to a degree of cross-
reactivity with other pathogens. On the other hand, testing an individual at early stage 
of HIV infection may results in false negative diagnosis. This should be also prevented 
to decease the widespread of the infection in the country. Our results are supported by 
the data obtained from different other ARCHITECT evaluations that were done on 
similar or higher numbers of samples from different countries (42-44)  
Our comparison between ARCHITECT results and the PCR results showed an 
overall percent agreement of 26.79%, indicating a very low agreement in the results 
obtained from the two assays. The PCR assay showed a significantly lower number of 
positive HIV cases compared to ARCHITECT (Table 5).  This may be due to the 
inability of PCR to identify some HIV infections, such as those on antiviral therapy. 
Indeed, reports from other laboratories using Nucleic acid amplification tests 
(NAAT) had shown that this technique might have several limitations in HIV screening 
as it is expensive and missing the detection of some HIV cases (19, 45). Moreover, the 
majority of the current PCR assays are designed to detect Subtype B HIV-1 but are not 




 Furthermore, seroconversion panels for non-HIV-1 subtypes and HIV-2 are not 
available (46). In addition, it is known that HIV subtypes differ according to the 
geographical distribution, where subtype C is the predominant type in India, 
Bangladesh, and Nepal (47, 48). Besides, many studies’ results supported our findings 
and showed high sensitivity and specificity of the ARCHITECT combination assay. 
For instance, a study aimed to evaluate the performance of ARCHITECT on well-
characterized specimens. Results showed that the initial ARCHITECT testing 
sensitivity was 99.94% and specificity was 98.78% (49). Another study showed that 
the specificity of the ARCHITECT was 99.5% and sensitivity 94% (50). Yet, it worth 
mention that Architect could generate a relatively high number of false positive results. 
In addition, newly infected individuals might be misdiagnosed as false negative  
(51).Therefore, detecting HIV antigens could shorten the window period and decrease 
the false negative results (52).Given that the Medical Health Commission is the main 
hub to screen individuals from different parts of the globe, with the majority coming 
from South Asian countries, makes it essential to carry tools that can detect all subtypes 
of HIV. Therefore, it is difficult to apply PCR as a specific tool to screen for HIV, and 
the ARCHITECT will remain the preferable technique used for massive screening of 
HIV. Future studies are needed to assess more the agreement between the two assays 
using a different set of primers that can detect different HIV subtypes.  
Improving the diagnostic tools for syphilis becomes an important concept to 
advance the level of care for STD patients. Different reports had shown frequent 
discrepancies in the results of the RPR test indicating the urgent need for regular quality 
control and enhancing the standards of the test (53). The inconsistent RPR titers 
between different laboratories raise doubts if this assay is the best to be used in syphilis 




outcomes. Conversely, our results showed 100% overall and positive percent 
agreements between two RPR tests done by two different dilutions and performed by 
two different technicians (Table 9).  Such consistency in the results indicates the 
validity of RPR at the Medical Health Commission and its crucial role as a reliable test. 
The differences in RPR results that have been seen in different laboratories could be 
due to a number of reasons such as storage of sample, freezing and thawing effects, and 
RPR test cards. There are many different RPR test cards available (BD Macro-Vue™ 
RPR and Carbon, Cypress Diagnostics) and each laboratory is using different cards; it 
could be the case that even within the same laboratory different cards are used. At the 
Medical Health Commission, all the test parameters had always been very consistent, 
which help to obtain such reproducible results. 
Our results demonstrated significant differences in the number of positive 
samples detected by RPR and ELISA, where the two methods showed a low overall 
percent agreement of 36.55% (Table 9). In agreement with other results, other studies 
had shown a non-statistically significant differences between the sensitivity of ELISA 
and the RPR test (54). It showed that ELISA is sensitive in all stages of the disease, 
while other studies showed that the assay is of low sensitivity during the early syphilis 
phase (29, 55). Furthermore, it has been previously shown that the ELISA sensitivity 
in detecting syphilis ranges from 45-100%. This wide range of sensitivity may be due 
to the type of ELISA used (56), stage of the disease (57), or laboratory environment 
and tools (58-61). Indeed, in our study, ELISA had been done in another institute 
(Hamad Medical Corporation), which may be the reason behind these differences 






  The main limitation of the study is that we did not have the diagnostic test 
results of HIV negative samples, so we could not calculate the specificity and sensitivity 
of the diagnostic test used. Therefore, we were not able to confirm the negative cases. 
Recommendations: 
  Since our data showed that there is a 100% agreement between the Architect 
result of the first and fresh repeat samples, we recommend not asking for repeat samples 
in order to save cost and time. Also, our data showed that there 100% agreement 
between the first run of RPR in comparison to the re-run by another lab technologist, 





CHAPTER 7: CONCLUSION  
 
   In conclusion, the techniques used in the Medical Health Commission are 
reliable and reproducible and efficient for the screening of STDs. Nevertheless, further 
studies are needed to test the agreement of these tests with other confirmatory tests done 
at Hamad Medical Corporation. Also, it is important to determine the cost-effectiveness 
of the implementation of these confirmatory tests in the Medical Health Commission 
laboratory to test the performance of these assays under the same environment and by 
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